Akorn, Inc. has entered into a 10-year exclusive contract manufacturing supply agreement with an undisclosed ophthalmic company. Under the terms of the agreement, Akorn will be responsible for the development, manufacturing and supply of two new ophthalmic products. The estimated manufacturing revenue from this agreement is $2–$3 million. The two products are targeted for launch in mid-2009.
   
Arthur S. Przybyl, Akorn’s president and chief executive officer stated, “This agreement reflects Akorn’s commitment to expanding our contract pharmaceutical manufacturing business unit.”